Phio Q1 net loss $3.6M; cash $9.0M; Phase 1 trial with AgonOx expected Q2 2023

Phio Pharmaceuticals Corp.

2023-Q1 EPS reported -$3.15

Net loss of $3.6M ($3.15 per share) vs $2.6M ($2.34 per share) in Q1 2022.
Cash at March 31, 2023: $9.0M, down from $11.8M at Dec 31, 2022; subsequent equity offering raised ~$1.7M net.
R&D expenses $2.1M (+35% YoY); G&A $1.5M (+39% YoY).
Expects to commence Phase 1 ACT trial with partner AgonOx by end of Q2 2023.
Cash expected to fund operations into Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Phio Pharmaceuticals Corp. reported the quarter ended March 31, 2023 results: net income Net loss increased 36% to approximately $3.6 million, EPS $3.15 per share.

Period: the quarter ended March 31, 2023
Net income: Net loss increased 36% to approximately $3.6 million
EPS: $3.15 per share
Result: reported results

Exact text from the filing

Net loss increased 36% to approximately $3.6 million, or $3.15 per share, for the quarter ended March 31, 2023

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-23-003214

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.